KR20240088231A - Sanguisorba officinalis Linne extracts that inhibits the activity of 3C-like protease in SARS-CoV-2 Omicron variant - Google Patents

Abstract

The present invention relates to the use of a novel oil extract to block or inhibit infection by SARS-CoV-2 omicron variants by inhibiting the activity of 3CL protease, a specific enzyme for the SARS-CoV-2 omicron variant virus. As related, the composition containing the oil extract of the present invention as an active ingredient is effective in preventing or treating infection by the SARS-CoV-2 variant virus by significantly inhibiting the activity of the 3CL protease of the SARS-CoV-2 omicron variant virus. It indicates that there is.

Description

Oil extract composition that inhibits the activity of 3C-like protease in SARS-CoV-2 Omicron variant {Sanguisorba officinalis Linne extracts that inhibits the activity of 3C-like protease in SARS-CoV-2 Omicron variant}

The present invention relates to the function of Sanguisorba officinalis Linne extract to inhibit SARS-CoV-2 omicron variant infection by inhibiting the activity of the specific 3CL protease (3C-like protease) of the SARS-CoV-2 omicron variant virus, and It's about his use.

Jiyu refers to cucumber plant and is a perennial plant belonging to the Rosaceae family. It is distributed in Korea, China, Japan, Russia, etc. and is a wild herb that grows in mountains and fields. Since ancient times, fat oil has been used as a detoxifier, burns, diarrhea, respiratory and gastrointestinal disease reliever, and various effects such as anti-allergy, anti-cancer, and antioxidant properties have been reported.

In general, methanol, ethanol, or water are used as solvents for extracting plants, and useful effects of oil hot water extract have been reported, including anticancer effects that inhibit cell proliferation of oral cancer, The effect of enhancing immunopotentiation has been reported in previous studies. Compared to other methods, the hot water extraction method can easily extract natural substances and obtain a large amount of useful ingredients. Since it is an extraction method that does not use chemical components such as ethanol, it has low toxicity, high efficacy of the extract, and can be used in food consumption. It can be said to be safe. In addition, Jiyu is a medicinal herb that grows in mountainous areas and has the advantage of being easy to cultivate, highly self-sustaining, and easily available.

Korean Patent No. 10-17842540000 discloses 'A composition for preventing or treating sepsis and a health functional food composition containing oil extract as an active ingredient', and Korean Patent Publication No. 2011-0117540 discloses 'A composition containing fat extract as an active ingredient'. 'Pharmaceutical compositions and health foods for the prevention or treatment of Helicobacter infectious diseases' containing There have been no reports of its effectiveness in preventing, improving, or treating infection with Severe acute respiratory syndrome coronavirus 2 Omicron variant.

The present inventors completed the present invention by confirming that the oil extract (QG1) is effective in preventing or treating infection caused by the SARS-CoV-2 omicron variant (B.1.1.529) virus, a variant of SARS-CoV-2. .

The technical problem to be achieved by the present invention is that a composition containing the active ingredient of oil extract (QG1) inhibits 3CL protease, an essential protein for the survival and division and proliferation of the SARS-CoV-2 omicron variant (B.1.1.529) virus. The goal is to treat and prevent diseases caused by the SARS-CoV-2 omicron variant virus.

In order to achieve the above object, the present invention provides a pharmaceutical for preventing or treating infection caused by SARS-CoV-2 Omicron variant virus (Severe acute respiratory syndrome coronavirus 2 Omicron variant) containing oil extract (QG1) as an active ingredient. A composition is provided.

In addition, a health functional food composition for preventing or improving infection by SARS-CoV-2 omicron variant virus containing oil extract as an active ingredient is provided.

Additionally, the step of drying the oil;

Extracting the dried fat with a solvent at 30 to 120°C; and

It provides a method for producing a pharmaceutical composition for preventing or treating infection by SARS-CoV-2 omicron variant virus, comprising the step of freeze-drying the extracted solution to prepare a powder.

The composition containing the oil extract (QG1) of the present invention as an active ingredient inhibits the activity of the specific 3CL protease of the SARS-CoV-2 omicron variant (B.1.1.529) virus. By blocking division and proliferation, it has a therapeutic effect on COVID-19 caused by the SARS-CoV-2 omicron variant virus.

Figure 1 is a diagram showing the results of inhibition of 3CL protease activity by negative control, positive control, and oil extract (QG1) against SARS-CoV-2 omicron variant (B.1.1.529) virus in in vitro assay. **, p <0.01; ***, p < 0.001
Figure 2 shows the results showing inhibition of the activity of 3CL protease specific to the SARS-CoV-2 omicron variant (B.1.1.529) virus through in vitro assay. The positive control and oil extract (QG1) compared to the negative control. This result indicates that the activity of 3CL protease is inhibited in a concentration-dependent manner.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for preventing or treating infection by SARS-CoV-2 omicron variant virus, comprising oil extract as an active ingredient.

SARS-CoV-2 is a virus that causes respiratory syndrome due to infection and is designated as a class 1 statutory infectious disease. It is currently causing a global pandemic and is causing very serious illness in people over 80, with a mortality rate of up to 25%. Invasion of SARS-CoV-2 into the nasal cavity through routes such as airborne droplets or person-to-person contact is considered the main cause of transmission.

SARS-CoV-2 that enters the human body binds to the ACE2 (Angiotensin-Converting Enzyme 2) receptor on the cell surface, penetrates into the cell, divides and proliferates, and generates a large amount of new viruses (Jackson CB., et al Mechanisms of SARS-CoV-2 entry into Cell. 2021, 5, 1-18. The resulting SARS-CoV-2 is secreted out of the cell again and proliferates by repeating the same process of re-infiltrating other cells. Therefore, the mechanisms involved in cellular infection, intracellular replication, and proliferation of SARS-CoV-2 are major targets for therapeutic development.

The genome of SARS-CoV-2 is composed of approximately 30,000 RNAs, and the spike protein of SARS-CoV-2 binds to the cell's ACE2 receptor (angiotensin converting enzyme 2), allowing SARS-CoV-2 to enter cells. enters and causes viral replication.

Crown-shaped spikes are characteristically expressed on the surface of the coronavirus. Spike protein consists of approximately 1,200 amino acids and consists of Spike 1 (S1) and Spike 2 domains (S2 domain). Functionally, S1 is known to be involved in cell receptor binding and S2 is involved in fusion.

The SARS-CoV-2 genome is known to encode proteins involved in viral replication and infection, such as viral polymerase and proteolytic enzymes, as well as structural proteins such as spike proteins.

SARS-CoV-2 is generating a number of mutant viruses, including omicron mutants, and these mutant viruses are mainly caused by genetic mutations in the spike domain, which plays a role in infiltrating host cells (Harvey , W.T., et al. SARS-CoV-2 variants, immune escape, Rev. 2021, 19, 409-424.

As used herein, SARS-CoV-2 virus may mean including its variants, and may specifically include variant viruses such as alpha, beta, gamma, delta, omicron, and mu, but is not limited thereto.

SARS-CoV-2 Omicron variant virus (B.1.1.529) is a mutant virus of SARS-CoV-2 newly discovered in Botswana on November 9, 2021. On November 26, WHO officially named it Omicron and classified it as a VOC (Variant of Concern).

The omicron mutant virus is mainly the first mutant virus with an overlapping purine cleavage mutation (P681H), and has both P681H, which caused enhanced infectiousness in the alpha mutation, and the N679K mutation observed in C.1.2. In addition, there are at least four vaccine evasion mutations (E484A, S477N, N440K, Q493R), and it also includes the amplification mutation K417N (B.1.1.529). Although less common than the lambda mutation, mutations occurred in two nucleocapsid protein locations (N:R203K, N:G204R). Additionally, the spike protein used by SARS-CoV-2 to infiltrate human cells includes A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N. , N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K and L Mutation 981F was observed. It is known that the number of mutations in the spike protein of the Omicron virus is more than six times that of the existing delta mutation (B.1.617.2).

The SARS-CoV-2 Omicron variant (B.1.1.529) virus has the highest drug resistance among the mutations discovered so far, and is estimated to have at least 5 mutations and up to 9 mutations. According to the research results of the South African Ministry of Health, 58 places in the RNA showed differences from the existing ones, of which 32 mutations occurred in the spike protein.

As used herein, the SARS-CoV-2 omicron variant (B.1.1.529) may include various subvariants, specifically BA.1, BA.1.1, BA.2, BA.2.12.1, It may include sub-variants such as BA.4, BA.5, BF.7, BQ.1, BQ.1.1, BA.2.75, BN.1, or XBB, but is not limited thereto.

Table 1 shows the SARS-CoV-2 omicron variant (B.1.1.529) and subvariants. The first lineage currently officially designated as an omicron variant of concern (VOC) is BA.1. Cases of BA.2 without the 69/70 deletion in the spike protein region are increasing in several countries such as India, South Africa, Denmark and the United Kingdom. BA.1.1 has an additional R346K mutation that is not present in other Omicron strains, and although BA.3 has fewer mutations in its spike protein and sequence monitoring data for BA.3 is limited, it still causes disease through viral transmission.

WHO label Omicron subvariants SARS-CoV-2 Omicron variant (B.1.1.529) BA.1 BA.1.1 BA.2 BA.2.12.1 BA.3 BA.4 BA.5 BA.7 BQ.1 BQ.1.1 BA2.75 BN.1 XBB

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) is an acute severe respiratory disease coronavirus 2 first known in 2019 and is a positive-sense single-stranded RNA virus. are classified. The disease caused by this virus was named coronavirus disease 2019 (Coronavirus disease 2019), and is abbreviated as COVID-19.

The disease caused by SARS-CoV-2 may be coronavirus infection-19. The coronavirus infection-19 may be a respiratory disease, and the respiratory disease may be pneumonia. The symptoms of COVID-19 may be at least one of fever, malaise, cough, difficulty breathing, phlegm, sore throat, headache, hemoptysis, nausea, and diarrhea.

The SARS-CoV-2 omicron virus may include variants thereof.

The variant may be characterized by a mutation occurring in the spike protein of the SARS-CoV-2 virus.

A composition containing the oil extract as an active ingredient may be characterized by inhibiting or inhibiting the activity of 3CL protease (3C-like protease) specific to SARS-CoV-2 omicron variants.

The 3CL protease, along with papain-like protease, is encoded in the SARS-CoV-2 omicron variant gene and is an essential protein for the production of functional proteins required for the in vivo proliferation of the SARS-CoV-2 omicron variant. The functional proteins required for proliferation encoded by are expressed in the form of a single polypeptide using the protein synthesis system of the host cell. What is unique is that each protein covalently linked within this polypeptide does not perform its own function, but can acquire function when it exists independently by being cleaved by protease (Anirudhan V., et al. Targeting SARS- CoV-2 viral proteases as a therapeutic strategy to treat COVID-19. J. Med. 2021, 93(5), 2722-2734.

3CL protease is known to produce functional proteins by acting on 11 cleavage sites present in polypeptides, while papain-like protease is known to produce functional proteins by acting on 3 cleavage sites. Therefore, when inhibiting 3CL protease, the production of multiple functional proteins can be inhibited compared to papain-like protease, so this enzyme may be a major target for the development of SARS-CoV-2 omicron variant virus therapeutics.

The present inventors screened for substances that inhibit the 3CL protease and RdRp protein specific to the SARS-CoV-2 omicron variant virus using hot water extracts of 223 herbal medicines to develop treatments and preventive agents for the SARS-CoV-2 omicron variant virus. Thus, the present invention was completed.

In a specific example of the present invention, an oil extract was prepared using fat oil, and the prepared extract was used in an in vitro test. As a result, compared to the negative control group that did not use oil extract, it showed the effect of inhibiting the division and growth of the SARS-CoV-2 omicron variant virus through inhibition of the activity of 3CL protease (Figures 1 and 2), according to the present invention. It was confirmed that the oil extract can be usefully used as a pharmaceutical composition for preventing or treating infection caused by the SARS-CoV-2 omicron variant virus.

In addition, as can be seen in Example 2 below, in the 3CL glow assay kit (Montana Molecular, USA) used for this experiment, the domain cleaved by 3CL protease is c- of the GFP (green fluorescent protein) protein. It is based on the GFP fusion protein attached to the terminal. While GFP fusion protein does not show fluorescence, pure GFP protein whose C-terminal fusion domain has been cleaved by 3CL protease shows fluorescence. In other words, if the activity of 3CL protease is inhibited, fluorescence generation from the GFP fusion protein is also reduced. Therefore, it was confirmed that the activity of the 3CL protease of the SARS-CoV-2 omicron variant virus was inhibited by the oil extract through the decrease in fluorescence production (Figure 1).

According to one embodiment of the present invention, the activity of 3CL protease is inhibited by oil extract compared to the negative control (H2O) in an in vitro model, thereby effectively inhibiting the survival and division and proliferation of the SARS-CoV-2 omicron variant virus. It was confirmed that there was (Example 2).

Therefore, it was confirmed that the oil extract of the present invention can be usefully used as a pharmaceutical composition for preventing or treating infection by the SARS-CoV-2 omicron variant virus.

The oil extract may be extracted with a solvent that is water, alcohol, or a mixture thereof.

The solvent may be water, ethanol, a lower alcohol having 1 to 5 carbon atoms, or an aqueous solution of a lower alcohol having 1 to 5 carbon atoms, but is not limited thereto.

The extraction temperature during extraction using the solvent is preferably 20°C to 130°C, 30°C to 120°C, and more preferably 90°C to 110°C, but is not limited thereto.

The pharmaceutical composition may include a pharmaceutically acceptable carrier, excipient, or diluent. The term "pharmaceutically acceptable" in the present invention means that the composition exhibits non-toxic properties to cells or humans exposed to the composition. The composition containing a pharmaceutically acceptable carrier may be in various oral or parenteral dosage forms. When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. The carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, It may be one or more selected from the group consisting of polyvinyl pyrrolidone, physiological saline, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, dextrin, calcium carbonate, propylene glycol, and liquid paraffin. It is not limited, and all common carriers, excipients, or diluents can be used. The ingredients may be added independently or in combination to the active ingredient, oil extract.

The pharmaceutical composition may be any selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. It can have one dosage form.

As a base for the suppository, witepsol, macrogol, tween 60, cacao, laurin, glycerogenatin, etc. may be used.

The pharmaceutical composition may have any one dosage form selected from the group consisting of powder, granule, tablet, capsule, and liquid form.

The pharmaceutical dosage form of the extract can be used alone or in combination with other pharmaceutically active compounds, as well as in appropriate combinations.

The pharmaceutical composition may be administered orally and may be a solid formulation or a liquid formulation. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include the extract with at least one excipient, such as starch, calcium carbonate, and sucrose. ) or prepared by mixing lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. there is. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.

The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount. There are no particular restrictions on the administered dose, and it may vary depending on body absorption, body weight, patient's age, gender, health condition, diet, administration time, administration method, excretion rate, and severity of disease. The pharmaceutical composition of the present invention is manufactured taking into account the effective dose range, and the unit dosage form formulated in this way can be prepared according to the judgment of an expert who monitors or observes the administration of the drug as needed and a specialized dosing method according to the individual's needs. It can be used or administered several times at regular time intervals. The above administration may preferably be administered once a day, or may be administered several times.

The oil extract may be extracted from one or more selected from the group consisting of the roots of Sanguisorba officinalis L. and the roots of Sanguisorba longifolia.

In addition, the present invention provides a food composition for preventing or improving infection by or disease caused by SARS-CoV-2 omicron variant virus, comprising oil extract as an active ingredient. The food may be characterized as being one or more of health functional foods or beverages.

When using the fat extract as a food additive, the fat extract can be added as is or used together with other foods or food ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). Generally, when producing a food or beverage, the extract of the present invention may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

There are no particular restrictions on the types of health functional foods. Examples of foods to which the oil extract can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, and drink preparations. , alcoholic beverages and vitamin complexes, etc., and can include all health functional foods in the conventional sense.

The health functional beverage composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, like ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame can be used.

In addition to the above health functional food, the health functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, and preservatives. , glycerin, alcohol, carbonating agents used in carbonated drinks, etc. Additionally, it may contain pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These ingredients can be used independently or in combination. The ratio of these additives is not very important, but is generally selected in the range of 0.01 to 2 parts by weight per 100 parts by weight of the composition of the present invention.

The oil extract is preferably prepared by a manufacturing method including the following steps, but is not limited thereto:

1) Drying the oil;

2) extracting the dried fat with a solvent at 30 to 120°C; and

3) Freeze-drying the extracted solution to produce powder.

The present invention includes the steps of 1) drying fat oil;

2) extracting the dried fat with a solvent at 30 to 120°C; and

3) It provides a method for manufacturing a pharmaceutical composition for preventing or treating infection by SARS-CoV-2 omicron variant virus, comprising the step of freeze-drying the extracted solution to prepare a powder.

In addition, the present invention includes the steps of 1) drying fat oil;

2) extracting the dried fat with a solvent at 30 to 120°C; and

3) It provides a method for manufacturing a health functional food composition for preventing or improving infection by the SARS-CoV-2 omicron variant virus, comprising the step of freeze-drying the extracted solution to produce a powder.

In the above method, the oil of step 1) can be used without limitation, such as cultivated or commercially available cucumber grass or long cucumber grass, and any leaves, roots, stems, and branches can be used, but are not limited to these, but are used according to the present invention. According to a preferred embodiment, it is most desirable to use the roots of cucumber grass or the roots of long cucumber grass.

In the above method, the extraction solvent in step 1) is preferably water, alcohol, alcohol, or a mixture thereof and an organic solvent. It is preferable to use a lower alcohol having 1 to 5 carbon atoms as the alcohol, and it is preferable to use ethanol or methanol as the lower alcohol. The extraction method is preferably, but not limited to, hot water extraction, shaking extraction, Soxhlet extraction, or reflux extraction. It is preferable to extract by adding 5 to 30 times the total weight of the dried oil, and more preferably by adding 20 times the extraction solvent to the total weight of the dried fat. The extraction temperature is preferably 20°C to 130°C, and more preferably 90°C to 110°C, but is not limited thereto. In addition, the extraction time is preferably 2 to 48 hours, more preferably 15 to 30 hours, and most preferably 24 hours, but is not limited thereto. In addition, the number of extractions is preferably 1 to 5 times, more preferably 3 to 4 times, and most preferably 3 times, but is not limited thereto.

The oil extract is preferably 30 to 95% alcohol extract, more preferably 40 to 90% alcohol extract, and most preferably 50 to 80% alcohol extract. In the case of less than 30% alcohol extract, the extraction efficiency This is lowered and may not show the intended prevention or treatment effect of infection by the SARS-CoV-2 omicron variant virus, and in the case of alcohol extract exceeding 95%, it is not good because it increases the production cost of the oil extract.

A composition containing fat extract as an active ingredient prepared through the above manufacturing method may be effective in preventing or treating infection by the SARS-CoV-2 omicron variant virus by inhibiting 3CL protease.

Hereinafter, the present invention will be described in detail through examples and experimental examples.

However, the following examples and experimental examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following examples and experimental examples.

Example 1. Preparation of oil extract

Distilled water 20 times the weight of the total weight of dried oil was added to dried oil (root of Sanguisorba officinalis Linne) and cold soaked for 1 hour and 30 minutes. Afterwards, the solution was extracted by refluxing at 100°C for 1 hour and 30 minutes using a large water boiler. The extracted solution was filtered under reduced pressure to remove impurities, and then freeze-dried at -20°C to prepare powder. 0.2 g of the freeze-dried oil powder was added to 10 mL of distilled water to prepare a solution containing oil extract (20 mg/ml), which was used in the test. In addition, the extraction solution from which impurities were removed by filtering under reduced pressure was spray dried to prepare powder. 0.2 g of the spray-dried oil powder was added to 10 mL of distilled water to prepare a solution containing oil extract (20 mg/ml), which was used in the experiment.

Example 2. Inhibition of specific 3CL protease activity and virus proliferation of SARS-CoV-2 omicron variant virus by oil extract

3CL protease in-vitro measurement and analysis were performed at the in vitro level as follows. This is an experiment to analyze the activity of 3CL protease (B.1.1.529, Omicron Variant) to determine whether the oil extract inhibits the division and proliferation of the SARS-CoV-2 Omicron variant virus.

This experiment used the 3CL protease (3C-like protease) inhibitor assay kit (BPS bioscience, USA) of the SARS-CoV-2 omicron variant virus. After reacting the test sample with a substrate that fluoresces when combined with the active site of 3CL protease, the fluorescence is measured using a known method to confirm the efficacy of the sample in inhibiting 3CL protease (B.1.1.529, Omicron Variant) activity. did. As a negative control, H2O was used in the same volume as the sample, and as a positive control for inhibiting 3CL protease activity, GC376 was used at 0.1, 1, and 10 μM, respectively. The reaction volume was 50 μl, and the treated oil extract was 2, 20, and 200 μg/ml, respectively.

As a result of the measurement, as shown in Figure 1, it was confirmed that compared to the negative control group, the oil extract treatment group inhibited the activity of 3CL protease to an equal or greater extent than the positive control group, and effectively inhibited the activity of 3CL protease in a concentration-dependent manner.

In addition, as shown in Figure 2, compared to the negative control group, both the freeze-dried fat extract group and the spray-dried fat extract group significantly inhibited the activity of the 3CL protease of the SARS-CoV-2 omicron variant virus to an equal or higher level than the positive control group. , it was found that the activity of 3CL protease was effectively inhibited in a concentration-dependent manner.

These results confirmed that the oil extract effectively inhibits the division and proliferation of the virus by inhibiting and blocking the 3CL protease action of the SARS-CoV-2 omicron variant.

Claims (17)

A pharmaceutical composition for preventing or treating infection by SARS-CoV-2 Omicron variant virus (Severe acute respiratory syndrome coronavirus 2 Omicron variant) containing oil extract as an active ingredient. In paragraph 1,
The SARS-CoV-2 omicron variant virus is characterized in that it includes subvariants, and the subvariants include BA.1, BA1.1, BA.2, BA.2.12.1, and BA.3. , BA.4, BA.5, BF.7, BQ.1, BQ1.1, BA.2.75, BN.1, or XBB. Pharmaceutical composition for preventing or treating infection. According to clause 1,
The composition is a pharmaceutical composition for preventing or treating infection by the SARS-CoV-2 omicron variant virus, characterized in that it inhibits the specific 3CL protease (3C-like protease) of the SARS-CoV-2 omicron variant. . According to clause 1,
A pharmaceutical composition for preventing or treating infection by SARS-CoV-2 omicron variant virus, characterized in that the oil extract is extracted with a solvent that is water, alcohol, or a mixture thereof. According to clause 1,
The pharmaceutical composition is a pharmaceutical composition for preventing or treating infection by SARS-CoV-2 omicron variant virus, characterized in that it contains a pharmaceutically acceptable carrier, excipient or diluent. According to clause 1,
The pharmaceutical composition is any one dosage form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, emulsions, freeze-dried preparations, and suppositories. A pharmaceutical composition for preventing or treating infection by SARS-CoV-2 omicron variant virus, characterized in that it has. According to clause 1,
The pharmaceutical composition is for the prevention or treatment of infection by the SARS-CoV-2 omicron variant virus, characterized in that it has any one formulation selected from the group consisting of powder, granule, tablet, capsule, and liquid form. Pharmaceutical composition. According to clause 1,
The oil extract is characterized in that it is extracted from one or more selected from the group consisting of the roots of Sanguisorba officinalis L. and the roots of Sanguisorba longifolia, for infection by the SARS-CoV-2 omicron variant virus. Pharmaceutical composition for prevention or treatment. A health functional food composition for preventing or improving infection by SARS-CoV-2 Omicron variant virus (Severe acute respiratory syndrome coronavirus 2 Omicron variant) containing oil extract as an active ingredient. According to clause 9,
The SARS-CoV-2 omicron variant virus is characterized in that it includes subvariants, and the subvariants include BA.1, BA1.1, BA.2, BA.2.12.1, and BA.3. , BA.4, BA.5, BF.7, BQ.1, BQ1.1, BA.2.75, BN.1, or XBB. Health functional food composition for preventing or improving infection. According to clause 9,
The composition is a health functional food composition for preventing or improving infection by the SARS-CoV-2 omicron variant virus, characterized in that it inhibits the SARS-CoV-2 omicron variant-specific 3CL protease (3C-like protease). drying the oil;
Extracting the dried fat with a solvent at 30 to 120°C; and
A method for producing a pharmaceutical composition for preventing or treating infection by SARS-CoV-2 omicron variant virus, comprising the step of freeze-drying the extracted solution to prepare a powder. According to clause 12,
The SARS-CoV-2 omicron variant virus is characterized in that it includes subvariants, and the subvariants include BA.1, BA1.1, BA.2, BA.2.12.1, and BA.4. , BA.5, BF.7, BQ.1, BQ1.1, BA.2.75, BN.1, or XBB, preventing infection by SARS-CoV-2 omicron variant viruses, or Method for preparing a therapeutic pharmaceutical composition. According to clause 12,
A method for producing a pharmaceutical composition for preventing or treating infection by SARS-CoV-2 omicron variant virus, wherein the solvent is at least one selected from the group consisting of water, alcohol, or mixtures thereof. According to clause 12,
A method of producing a pharmaceutical composition for preventing or treating infection by SARS-CoV-2 omicron variant virus, wherein the pharmaceutical composition contains a pharmaceutically acceptable carrier, excipient, or diluent. According to clause 12,
The pharmaceutical composition is any one dosage form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, emulsions, freeze-dried preparations, and suppositories. A method for producing a pharmaceutical composition for preventing or treating infection by SARS-CoV-2 omicron variant virus, characterized in that it has. According to clause 12,
The pharmaceutical composition is for the prevention or treatment of infection by the SARS-CoV-2 omicron variant virus, characterized in that it has any one formulation selected from the group consisting of powder, granule, tablet, capsule, and liquid form. Method for preparing pharmaceutical compositions.